362 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
ABT Abbott Laboratories $67.67 $118.71B N/A
Article Searches
Story Stocks: Abbott Labs' diabetes care unit shines, but stock flutters on mediocre cardiovascular results (ABT) https://www.briefing.com/in-depth-analysis/Content/Article?ArticleId=NS20191016103542StoryStocks Oct 16, 2019 - In September of 2017, medical device company Abbott Labs (ABT) launched a new glucose monitoring sys
Abbott Forms Alliance With Omada Health for Diabetes Care http://www.zacks.com/stock/news/565703/abbott-forms-alliance-with-omada-health-for-diabetes-care?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-565703 Oct 15, 2019 - Abbott (ABT) collaborates with Omada Health to revolutionize diabetes care by expanding technological access.
Abbott (ABT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release http://www.zacks.com/stock/news/556156/abbott-abt-earnings-expected-to-grow-what-to-know-ahead-of-next-weeks-release?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-556156 Oct 09, 2019 - Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abbott (ABT) Gets FDA Nod for New Troponin-I Blood Test http://www.zacks.com/stock/news/545891/abbott-abt-gets-fda-nod-for-new-troponin-i-blood-test?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-545891 Oct 02, 2019 - The regulatory go-ahead for Abbott's (ABT) ARCHITECT STAT High Sensitivity Troponin-I blood test is a major stride forward in its commitment for detecting patients suspected of having a heart attack.
Abbott (ABT) Gets FDA Nod for Spinal Cord Stimulation System http://www.zacks.com/stock/news/544418/abbott-abt-gets-fda-nod-for-spinal-cord-stimulation-system?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-544418 Oct 01, 2019 - Abbott (ABT) is upbeat about the latest clearance in its neuromodulation product portfolio.
CGM Devices Gain Steam, Set New Trend in Diabetes Management http://www.zacks.com/stock/news/527773/cgm-devices-gain-steam-set-new-trend-in-diabetes-management?cid=CS-ZC-FT-analyst_blog|industry_focus-527773 Sep 20, 2019 - The FDA authorization classifies the new type of CGM devices in class II and subjects these to certain criteria called special controls.
Abbott Receives European Nod for Pediatric Heart Devices http://www.zacks.com/stock/news/524246/abbott-receives-european-nod-for-pediatric-heart-devices?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-524246 Sep 18, 2019 - Abbott (ABT) aims to offer better treatment options for the most vulnerable patient population.
Abbott Partners With Sanofi to Upgrade Diabetes Management http://www.zacks.com/stock/news/522662/abbott-partners-with-sanofi-to-upgrade-diabetes-management?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-522662 Sep 17, 2019 - Abbott (ABT) collaborates with Sanofi to revolutionize diabetes care through technological advancements.
Here's Why You Should Hold on to Thermo Fisher (TMO) for Now http://www.zacks.com/stock/news/499537/heres-why-you-should-hold-on-to-thermo-fisher-tmo-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-499537 Sep 03, 2019 - Investors continue to be optimistic about Thermo Fisher's (TMO) performance.
Abbott (ABT) Hits New 52-Week High on Solid Growth Drivers http://www.zacks.com/stock/news/430392/abbott-abt-hits-new-52-week-high-on-solid-growth-drivers?cid=CS-ZC-FT-430392 Jun 17, 2019 - Abbott (ABT) gains from expansion of product portfolio and several regulatory clearances.

Pages: 1234567...37

<Page 2>